Commentary: IMRT for head and neck cancer: Many chapters left to write

Oncologist

Volumn 12, Issue 5, 2007, Pages 565-568

  Allen, Aaron M ^a,b   Tishler, Roy B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MUCOSAL DISEASE; NASOPHARYNX CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; PARANASAL SINUS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; REVIEW; SKULL INJURY; TREATMENT OUTCOME; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RELATIVE BIOLOGICAL EFFECTIVENESS; TUMOR BURDEN;

EID: 35548955018     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-5-565     Document Type: Review

References (33)

1. Bussels B, Maes A, Hermans R et al. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol 2004;72:119-127.
2. Grégoire V, De Neve W, Eisbruch A et al. Intensity-modulated radiation therapy for head and neck carcinoma. The Oncologist 2007;12:555-564.
3. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7.
4. Hsiung CY, Hunt MA, Yorke ED et al. Intensity-modulated radiotherapy as the boost or salvage treatment of nasopharyngeal carcinoma: The appropriate parameters in the inverse planning and the effect of patient's anatomic factors on the planning results. Radiother Oncol 2005;77:53-57.
5. Hunt MA, Zelefsky MJ, Wolden S et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001;49:623-632.
6. Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
7. Wolden SL, Chen WC, Pfister DG et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
8. Wolden SL, Zelefsky MJ, Hunt MA et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2001;49:1229-1234.
9. Eisbruch A, Marsh LH, Dawson LA et al. Recurrences near base of skull after IMRT for head-and-neck cancer: Implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys, 2004;59:28-42.
10. Sanguineti G, Culp LR, Endres EJ et al. Are neck nodal volumes drawn on CT slices covered by standard three-field technique? Int J Radiat Oncol Biol Phys 2004;59:725-742.
11. McGinn CJ, Harari PM, Fowler JF et al. Dose intensification in curative head and neck cancer radiotherapy-linear quadratic analysis and preliminary assessment of clinical results. Int J Radiat Oncol Biol Phys 1993;27:363-369.
12. Fowler JF. Fractionation factors for late effects in head and neck cancers. Int J Radiat Oncol Biol Phys 1992;22:219.
13. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48):7-16.
14. Mohan R, Wu Q, Manning M et al. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000;46:619-630.
15. Horiot JC, Le Fur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
16. Horiot JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
17. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2006:1-546.
18. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
19. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
20. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
21. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
22. de Arruda FF, Puri DR, Zhung J et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006;64:363-373.
23. Eisbruch A, Schwartz M, Rasch C et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004;60:1425-1439.
24. Eisbruch A, Ship JA, Dawson LA et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003;27:832-837.
25. Eisbruch A, Kim HM, Terrell JE et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
26. Lin A, Kim HM, Terrell JE et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003;57:61-70.
27. Kam MK, Leung SF, Zee B et al. Impact of intensity-modulated radiotherapy (IMRT) on salivary gland function in early-stage nasopharyngeal carcinoma (NPC) patients: A prospective randomized study. Proc Am Soc Clin Oncol 2005;23:Abstract 5501.
28. Thorstad WL, Chao KS, Haughey B. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 2004;31(suppl 18):8-12.
29. Rosenthal DI, Chambers MS, Weber RS et al. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol 2004;31(suppl 18):25-28.
30. Second cancers after radiotherapy for Hodgkin's disease. N Engl J Med 1988;319:244-246.
31. Yahalom J, Petrek JA, Biddinger PW et al. Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992;10:1674-1681.
32. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-88.
33. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.